The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.
Glioblastoma Multiforme, Adult
BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)
Number of adverse events related to TiLs infusion, The primary outcome measure of this clinical trial is accessed by the safety of the TILs product. The safety profile for TILs is characterized by its incidence of the adverse events., 1 month
Progressional free of survival (PFS), PFS is defined as the duration of time from start of treatment to time of progression. All patients will be followed for a minimum of 2 years., Up to 24 months|Objective response rate (ORR), 24 months
The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.